Fung Ching-kee Appears at Summit, Silent on Embryo Mix-up
SingTao · 1 SOURCESabout 1 hour ago2 MIN
Summary
New Frontier Group co-founder and former Financial Secretary Antony Leung Kam-chung made his first public appearance since the embryo mix-up scandal at the company's Global Healthcare Summit on July 7, but did not speak to the media about the incident . The two-day summit at the Hong Kong Convention and Exhibition Centre attracted over 3,000 participants to discuss AI technology and medical research . The event was co-organized with Hong Kong Investment Corporation Limited, whose CEO Clara Chan Ka-kai delivered opening remarks . The embryo mix-up at subsidiary HKC Reproductive Medicine Centre remains under police investigation, with a female staff member suspected of having fled Hong Kong and currently wanted by authorities .
Key Points
- Former Financial Secretary Antony Leung Kam-chung, co-founder and chairman of New Frontier Group, appeared publicly for the first time since the embryo scandal but declined media interviews .
- The second Global Healthcare Summit opened on July 7 at the Hong Kong Convention and Exhibition Centre with over 3,000 attendees discussing AI and medical research .
- Hong Kong Investment Corporation CEO Clara Chan Ka-kai stated the firm aims to help enterprises grow from "zero to one" and "one to infinity" in commercialization .
- New Frontier Group CEO Wu Qinan warned that by 2050, nearly 2.1 billion people globally will be elderly, with rising cancer and diabetes cases .
- A female staff member at HKC Reproductive Medicine Centre allegedly fabricated statements and fled Hong Kong the day after giving a recorded interview, with police classifying the case as fraud .
Why It Matters
The incident raises serious concerns about regulatory oversight of reproductive technology facilities in Hong Kong and the accountability of major healthcare conglomerates . The co-location of a global medical summit with an unresolved embryo scandal involving the parent company highlights tensions between Hong Kong's ambitions as a healthcare hub and the need for stronger patient safeguards .
The incident raises serious concerns about regulatory oversight of reproductive technology facilities in Hong Kong and the accountability of major healthcare conglomerates . The co-location of a global medical summit with an unresolved embryo scandal involving the parent company highlights tensions between Hong Kong's ambitions as a healthcare hub and the need for stronger patient safeguards .